Antibody-drug conjugates show distinct safety profiles and improve quality of life in metastatic breast cancer.
HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...
OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, is pleased to invite investors to a webinar ...
In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...
OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced the formation of subsidiary OS Drug ...
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
News Medical on MSN21h
Novel cancer treatment uses bacterial toxin to train immune systemResearchers at the University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) ...
The firm is focusing on specialty chronic therapies like immunotherapy, antibody-drug conjugates, and gene therapy drugs, ...
As OS Therapies prepares to take its bacteria-based lung cancer therapy to the FDA for approval, the biotech has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback